Egetis Therapeutics

• Van Lanschot Kempen is pleased to have served as Joint Bookrunner to Egetis Therapeutics, an orphan drug company focused on developing and commercialising treatments for serious diseases with high unmet medical need, on the successful completion of its SEK 350m equity financing via an accelerated bookbuild offering
• The transaction was launched following a market sounding exercise, which indicated higher demand than deal size at launch
• The accelerated bookbuild offering was oversubscribed and priced at market, i.e. equivalent to the closing price prior to launch, attracting strong demand from new high quality biotech specialist and long-only investors, and continued strong participation from existing shareholders
• The Company’s share price has traded up c.15% following the transaction, reflecting positive market reception
• The proceeds from the offering will primarily be used to fund the commercial launch preparations for Emcitate (tiratricol) in the United States and support the planned indication expansion into Resistance to Thyroid Hormone beta (RTH-β)
• This transaction marks Van Lanschot Kempen’s 10th transaction in the rare disease space over the past year, underscoring our strong expertise and experience in this area across equity and debt financing, and M&A
• Over the past 12 months, Van Lanschot Kempen has raised c.€2.0 billion in financing in a leading role, including c. €500 million for clients in the Nordics, highlighting our strong track record in the region

Egetis Therapeutics, listed on Nasdaq Stockholm (ticker: EGTX), is a late-stage pharmaceutical company focused on developing and commercialising treatments for serious diseases with high unmet medical need. The Company’s lead product, Emcitate (tiratricol), is being developed for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan-Herndon-Dudley Syndrome (AHDS), a rare X-linked genetic disorder. The Company has also received Orphan Drug Designation for Emcitate in Resistance to Thyroid Hormone beta (RTH-β).

Egetis received marketing authorisation for Emcitate in the EU in February 2025 and initiated commercial launch in Germany in May 2025, making it the first and only approved therapy for MCT8 deficiency in the EU. In the United States, the Company completed its NDA rolling submission in January 2026, followed by FDA acceptance of the filing and the granting of Priority Review in March 2026. The PDUFA target action date is set for 28 September 2026.

In the last eighteen months, Van Lanschot Kempen has successfully completed a large number of successful transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Joint Book-Running Manager in AgomAb Therapeutics’ USD 200m Initial Public Offering on US Nasdaq
• Sole Global Coordinator & Joint Bookrunner in the €105 million Capital Increase by Transgene
• Joint Bookrunner in the SEK 672 million Capital Increase by Hansa Biopharma
• Joint Bookrunner in the USD 345 million Capital Increase by uniQure
• Joint Bookrunner in the secondary sell-down of existing BioArctic shares for SEK 720 million
• Co-Manager in the USD 110 million financing by Oculis
• Financial Adviser to Galapagos in the sale of a portfolio of oncology and immunology programmes to Onco3R
• Co-Manager in the USD 748 million Capital Increase by Abivax
• Financial Adviser in MaaT Pharma’s €38 million venture debt facility from the European Investment Bank
• Joint Bookrunner in the USD 201 million Capital Increase by Pharvaris
• Lead Manager in the USD 345 million Capital Increase by Merus
• Co-Placement Agent in DBV Technologies’ up to USD 307 million financing
• Placement Agent in MaaT Pharma’s €13 million Capital Increase
• Sole Financial Adviser in Pharming’s SEK 725 million public takeover of Abliva
• Sole Financial Adviser in GENFIT’s royalty financing up to €185 million
• Sole Financial Adviser in IO Biotech’s c. €58 million loan facility from the European Investment Bank
• Financial Adviser in the USD 479 million US Public Offering by NewAmsterdam Pharma
• Sole Financial Adviser to SNIPR Biome in securing a €20 million venture debt facility from the European Investment Bank